AbCellera Biologics
ABCL
124 hedge funds and large institutions have $1.63B invested in AbCellera Biologics in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 25 closing their positions.
133% more call options, than puts
Call options by funds: $43.3M | Put options by funds: $18.6M
47% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 30
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
7% more funds holding
Funds holding: 116 → 124 (+8)
5.27% more ownership
Funds ownership: 35.41% → 40.68% (+5.3%)
18% less capital invested
Capital invested by funds: $1.98B → $1.63B (-$349M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$33.8M |
| 2 |
BlackRock
New York
|
+$21.1M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$20.4M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$15.5M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$19.5M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$10.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$6.78M |
| 4 |
E
Ergoteles
New York
|
-$6.64M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.47M |
ABCL Hedge Fund Activity: Q4 2021 in Review
124 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2021, worth a combined $1.63B — down 18% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ABCL positions and 25 closed out — a net gain of 8 holders — while 44 added to existing stakes and 30 trimmed.
The largest buyer was Capital World Investors, adding an estimated $33.8M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $19.5M sold.
- 124 institutional investors held AbCellera Biologics (ABCL) as of Q4 2021, up from 116 in Q3 2021.
- Funds reported $1.63B of AbCellera Biologics stock for Q4 2021, down 18% quarter-over-quarter.
- 33 funds opened new AbCellera Biologics positions in Q4 2021 and 25 closed out, a net change of +8 holders.
- The largest AbCellera Biologics buyer in Q4 2021 was Capital World Investors, an estimated $33.8M added.
- The largest AbCellera Biologics seller in Q4 2021 was Clough Capital Partners, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2021.